The estimated Net Worth of Lewis Clayton Jr. Cantley is at least 16.3 百万$ dollars as of 6 December 2017. Dr Cantley owns over 3,838 units of Agios Pharmaceuticals Inc stock worth over 3,523,310$ and over the last 10 years he sold AGIO stock worth over 12,788,362$.
Dr has made over 35 trades of the Agios Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 3,838 units of AGIO stock worth 227,862$ on 6 December 2017.
The largest trade he's ever made was selling 10,664 units of Agios Pharmaceuticals Inc stock on 28 December 2015 worth over 692,414$. On average, Dr trades about 4,494 units every 27 days since 2014. As of 6 December 2017 he still owns at least 79,515 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Dr Cantley stock trades at the bottom of the page.
Dr. Lewis Clayton Cantley Ph.D. is the Co-Founder & Member of Scientific Advisory Board at Agios Pharmaceuticals Inc.
Dr D is 72, he's been the Co-Founder & Member of Scientific Advisory Board of Agios Pharmaceuticals Inc since . There are 2 older and 21 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.
Lewis's mailing address filed with the SEC is 88 Sidney St, Cambridge, MA 02139, USA.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over 77,887,085$ worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth 154,554,190$ . The most active insiders traders include Kevin P Starr、Robert Nelsen、John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 765,588$. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth 102,002$.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: